Study of Oral MRT-2359 in Selected Cancer Patients

NCT05546268 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

174

Enrollment

INDUSTRY

Sponsor class

Conditions

NSCLC
SCLC
High Grade Neuroendocrine Cancer
DLBCL
L-MYC and N-MYC Amplified Solid Tumors
NSCLC With High or Low L-MYC or N-MYC Expression
HR-positive, HER2-negative Breast Cancer
Prostate Cancer

Interventions

DRUG: Oral MRT-2359
DRUG: Oral MRT-2359
DRUG: Oral MRT-2359
DRUG: Oral MRT-2359
DRUG: Oral MRT-2359
DRUG: Oral MRT-2359

Sponsor

Monte Rosa Therapeutics, Inc